This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific Acquires Neovasc to Boost Heart Business
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of specialty medical device company Neovasc Inc.'s (NVCN) tissue processing technology.
Inovalon (INOV) Cuts 2016 Revenue and Earnings Guidance
by Zacks Equity Research
Inovalon Holdings (INOV), lowered its revenue and earnings guidance for full-year 2016.
Haemonetics' Plasma Group Impresses, Blood Center a Drag
by Zacks Equity Research
On Dec 12, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE).
Align Up on Balanced Growth, Expansion of Invisalign Teen
by Zacks Equity Research
On Dec 9, 2016, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Genomic Health Posts Impressive Data for Oncotype DX Test
by Zacks Equity Research
Genomic Health Inc. (GHDX) recently unveiled positive findings of its Oncotype DX test in individualizing breast cancer treatment decisions for patients at various stages of the disease.
Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart
by Zacks Equity Research
Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart
Amedisys Down on Dismal Quarter, Reimbursement Headwind
by Zacks Equity Research
On Dec 8, we issued an updated research report on Baton Rouge, LA-based Amedisys Inc. (AMED).
5 Efficient Stocks to Buy for Superlative Returns
by Zacks Equity Research
Investors seeking impressive returns irrespective of market conditions may consider adding stocks with favorable efficiency levels to their portfolios.
Haemonetics Introduces Upgraded NextGen DMS 4 Software
by Zacks Equity Research
Haemonetics Corporation (HAE) recently unveiled upgraded NextGen DMS (Donor Management System) to augment plasma collection center operations.
Henry Schein Buys Stake in Marrodent; Spurs Polish Foothold
by Zacks Equity Research
Henry Schein (HSIC) has recently completed its earlier announced purchase of 80% ownership of Marrodent.
Steris Poor Q2 Disappoints, Synergy Health Raises Hope
by Zacks Equity Research
On Dec 7, we issued an updated research report on OH-based STERIS plc (STE).
Masimo (MASI) Hits 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Share price of Irvine, CA-based Masimo Corporation (MASI) reached a new 52-week high of $63.45 on Dec 7, finally closing a tad lower at $62.17.
Henry Schein's Q3 Results Impress, Pricing Pressure a Drag
by Zacks Equity Research
On Dec 6, we issued an updated research report on Melville, NY-based Henry Schein Inc. (HSIC).
Medtronic Teams Up with Fitbit, Accelerates Diabetic Care
by Zacks Equity Research
Medtronic recently joined forces with Fitbit (FIT) to create an integrated diabetes care management program.
Genomic Health: Cancer Test Business Strong, Q3 Dismal
by Zacks Equity Research
On Dec 6, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).
Medtronic Endurant II/IIs Stent Graft System Wins CE Mark
by Zacks Equity Research
Medtronic plc (MDT) recently won CE mark for its Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients through a ChEVAR procedure.
GNC Faces Poor Domestic Sales, Margins Still Under Pressure
by Zacks Equity Research
On Dec 5 2016, we issued an updated research report on Pittsburgh, PA-based GNC Holdings, Inc. (GNC).
Omnicell Unveils XT Series Automated Dispensing System
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently introduced a new generation of medication and supply automation that is fully integrated with the company's Unity enterprise platform -- XT series.
Bruker Ties Up with IPCN to Boost Preclinical Imaging Suite
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced that it has become the key corporate partner of The International Phenome Centre Network (IPCN).
Boston Scientific (BSX) Inks $75 Million Deal with Neovasc
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently inked a deal with specialty medical device company Neovasc Inc.
Medtronic Introduces CoreValve Evolut R System in Japan
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of reimbursement approval from MHLW for its transcatheter CoreValve Evolut R System.
Neogen (NEOG) to Buy Quat-Chem, Shares Hit 52-Week High
by Zacks Equity Research
Neogen Corporation (NEOG), recently announced the acquisition of United Kingdom-based Quat-Chem Ltd., a chemical company which develops, manufactures and sells agricultural, industrial, and food processing biocidal hygiene products.
Omnicell to Buy Ateb, Expand in Adherence Tools Market
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently inked a deal to buy pharmacy-based patient care solution provider Ateb, Inc and its Canadian affiliate, Ateb Canada Ltd.
Medtronic Stock Falls on Mixed 2Q; Positive on HeartWare Buy
by Zacks Equity Research
On Nov 30, 2016, we issued an updated research report on medical device major, Medtronic plc (MDT).
Medtronic Partners UH to Launch Integrated Health Solutions
by Zacks Equity Research
Medtronic plc (MDT) recently announced the signing of its Integrated Health Solutions agreement with University Hospitals (UH) in the U.S.